ImmuPharma plc Completion of Lanstead Sharing Agreement

ImmuPharma plc (LSE: IMM), the specialist drug discovery and development company, wishes to announce the completion of the Sharing Agreement entered into with Lanstead Capital L.P. in February 2016.

As announced on 5 February 2016, Lanstead subscribed for GBP4.4 million of new ordinary shares in ImmuPharma, with both parties also entering into the Sharing Agreement. All 18 settlements of the Sharing Agreement have now been completed. Through both the subscription and Sharing Agreement, ImmuPharma has received a total of just over GBP5.0 million from Lanstead, with a net gain of GBP0.6 million more than originally subscribed.

Tim McCarthy, Chairman of ImmuPharma, commented: “Lanstead has been an important supporter of ImmuPharma and we are delighted how effectively the Sharing Agreement has worked for both parties. We look forward to a continued supportive relationship with Lanstead as ImmuPharma seeks to create long term shareholder value within its asset portfolio and specifically our focus on hitting key milestones within our lead programme Lupuzor(TM), as we get nearer to reporting top-line Phase III results in Q1 2018.”

Nicholas Malins-Smith of Lanstead, commented: “We are delighted to have been able to be supportive in the progression of ImmuPharma’s pivotal Phase III clinical trial of Lupuzor(TM). Through the Sharing Agreement with Lanstead, ImmuPharma has been able to benefit, through the increase in its share price, by securing additional funds over and above the original subscription amount.

“Lanstead is pleased to remain a supportive shareholder of ImmuPharma and looks forward to the Company’s further progress.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Immupharma Plc

    More articles like this

    Immupharma Plc

    Learning About Lupus

    May is Lupus Awareness Month. It is a disease that is relatively common in the Caribbean yet many of us are unfamiliar with the condition. Lupus is an autoimmune condition that can affect almost every system

    Immupharma Plc

    ImmuPharma Change of Registered Office Address

    ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today announced that with immediate effect, its registered office address has been changed to: One Bartholomew Close, London, EC1A 7BL.

    Immupharma Plc

    ImmuPharma Change of AGM Venue

    ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, today announced that the Company’s Annual General Meeting confirmed for Thursday, 18 June 2020 @ 10.30am, will now be held at: 52 Grosvenor Garden, London SW1W 0AU. The COVID-19

    Immupharma Plc

    Lupus Latest Facts: Causes, Symptoms and Treatments

    Lupus is a relatively rare inflammatory disease. In the US 1.5 million are currently living with the condition. It is an autoimmune disease that can affect various organs including the skin, joints, kidneys, and brain. What

    Immupharma Plc

    Selena Gomez urges fans to join the fight against Lupus

    US singer Selena Gomez has urged her fans across the world to join the fight against Lupus, an autoimmune disease. The disease leads to the body’s immune system becoming hyperactive, attacking normal and healthy tissues. On

    Immupharma Plc

    Understanding Lupus

    Lupus is a chronic (long-term) disease that can cause inflammation and pain in any part of your body. It’s an autoimmune disease, which means that your immune system — the body system that usually fights infections

    Immupharma Plc

    What to know about COVID-19 and lupus

    Lupus is a chronic autoimmune condition in which the immune system attacks its own tissues. People with lupus are at higher risk of infections, and those with lupus who develop COVID-19 may be at higher risk

    Immupharma Plc

    Frequently asked questions: coronavirus (COVID-19) and lupus

    Our Health Educator Network—health-care professionals and lupus specialists who provide individualized answers—have seen their inquires triple in the last week. The following are questions they’ve been frequently asked and their answers. Should I wear a facemask?

    Immupharma Plc

    Are People with Lupus Protected Against COVID-19?

    There is no evidence that taking hydroxychloroquine (Plaquenil) is effective in preventing a person from contracting the coronavirus (COVID-19). People with lupus should follow the guidance of their doctor and the safety guidelines being issued by

    Immupharma Plc

    Dr Miriam Stoppard on Lupus

    Lupus isn’t that common but when it strikes it can be very ­serious, even life-threatening. The story of the singer and ­actress Selena Gomez is a case in point. All lupus sufferers will be grateful to her because